Michael Powell's Net Worth

$242 Million

Who is Michael Powell?

Michael Powell has an estimated net worth of $242 Million. This is based on reported shares across multiple companies, which include AMARIN CORP PLC\UK, COTHERIX INC, Orexigen Therapeutics, Inc., Trius Therapeutics Inc, ANESIVA, INC., HYPERION THERAPEUTICS INC, MARINUS PHARMACEUTICALS INC, HISTOGENICS CORP, Vera Therapeutics, Inc., Aclaris Therapeutics, Inc., AERIE PHARMACEUTICALS INC, Inozyme Pharma, Inc., KALOBIOS PHARMACEUTICALS INC, Entasis Therapeutics Holdings Inc., Iterum Therapeutics plc, Checkmate Pharmaceuticals, Inc., Galera Therapeutics, Inc., Bolt Biotherapeutics, Inc., Principia Biopharma Inc., NextCure, Inc., SYNLOGIC, INC., THRESHOLD PHARMACEUTICALS INC, aTYR PHARMA INC, ALIMERA SCIENCES INC, Akouos, Inc., NOVACEA INC, Durata Therapeutics, Inc., Versartis, Inc., SEATTLE GENETICS INC /WA, Anthera Pharmaceuticals Inc, Spark Therapeutics, Inc., and Ocera Therapeutics, Inc..

SEC CIK

Michael Powell's CIK is 0001202793

Past Insider Trading and Trends

2013 was Michael Powell's most active year for acquiring shares with 40 total transactions. Michael Powell's most active month to acquire stocks was the month of April. 2004 was Michael Powell's most active year for disposing of shares, totalling 174 transactions. Michael Powell's most active month to dispose stocks was the month of November. 2007 saw Michael Powell paying a total of $15,000,001.20 for 6,551,558 shares, this is the most they've acquired in one year. In 2015 Michael Powell cashed out on 25,223,373 shares for a total of $89,215,804.00, their largest year based on trade value.